Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553459 | 0.81 | MEN1 (0.38) | MEN1KMT2APSEN1PSEN2APH1B | |
| SCHEMBL13780923 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15830080 | 0.77 | TP53 (0.38) | MEN1KMT2A | |
| SCHEMBL15384938 | 0.76 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL4444854 | 0.74 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL13780657 | 0.74 | MEN1 (0.33) | MEN1KMT2APSEN1PSEN2APH1B | |
| SCHEMBL12967465 | 0.73 | PSEN1 (0.37) | MEN1KMT2APSEN1PSEN2APH1B | |
| SCHEMBL15384936 | 0.71 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL15384963 | 0.71 | LMNA (0.37) | MEN1KMT2APSEN1PSEN2APH1B | |
| SCHEMBL12967478 | 0.71 | MEN1 (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231628-B1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2009088719-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | CHRNB2 2946/4885CHRNA4 4243/4885CHRNB4 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.